High-Dose Flu Vaccine Significantly Boosts Protection for Veterans

Influenza, commonly known as the flu, poses a significant public health threat, particularly to vulnerable populations like elderly individuals and veterans who may have compromised immune systems or underlying health conditions. While annual vaccination is the primary defense, questions persist regarding the optimal vaccine formulation for maximum protection. This study addresses the crucial knowledge gap of whether high-dose influenza vaccines offer superior effectiveness compared to standard-dose vaccines in a real-world veteran population.

The study revealed that the high-dose quadrivalent influenza vaccine provided significantly better protection compared to the standard-dose vaccine in the veteran population. Recipients of the high-dose vaccine experienced a 24% relative reduction in influenza-related hospitalizations (p<0.001) and an 18% relative reduction in influenza-related outpatient visits (p<0.01). This enhanced protection was consistent across both the 2015–2016 and 2016–2017 seasons, demonstrating robust and reproducible benefits. The most significant finding was a 32% relative reduction in all-cause mortality among high-dose vaccine recipients compared to those receiving the standard-dose vaccine (p<0.0001), highlighting a substantial survival benefit. Furthermore, the high-dose vaccine showed a 1.5-fold increase in antibody response in a subset of patients, suggesting a stronger immune activation mechanism.